LifeTech expects H1 net loss attributable to owners of RMB 30 million-RMB 40 million vs year-ago profit

• LifeTech flagged a sharp earnings drop for the six months ended June 30, 2026, based on unaudited management accounts.
• Net profit attributable to owners, excluding non-recurring items, seen at RMB 110-120 million, down from RMB 238.5 million a year earlier.
• Including non-recurring items, net result expected to swing to a loss of RMB 30-40 million from a profit of RMB 55.1 million.
• Decline driven by lower revenue, weaker net exchange gains, transaction expenses tied to a scrapped Starway Medical equity acquisition.
• Interim results for the period are expected by end-August 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeTech Scientific Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260812-12281935), on August 12, 2026, and is solely responsible for the information contained therein.